Early Cancer Detection with Luminex Assays

Why Luminex Assays for Early Cancer Detection?

Capture Complex Biology with Multiplexing

Cancer is driven by dynamic interactions across cytokines, growth factors, and tumor markers. Luminex assays enable you to identify these networks by measuring up to 50 analytes simultaneously from minimal sample volume—providing system-level insight into early disease processes. 

Enhance Sensitivity and Specificity

Advances in proteomics and multiplex immunoassays have improved analytical performance, enabling detection of subtle biomarker changes associated with early-stage disease at concentrations as low as 0.06 pg/mL. Detecting low-abundance biomarkers—such as early-stage tumor cytokines—requires assays with both exceptional sensitivity and specificity. In multiplex settings, this challenge is even greater: the assay must remain sensitive enough to detect subtle changes while avoiding cross-reactivity among closely related proteins. The key lies in antibody quality. R&D Systems Luminex High-performance Assays rely on rigorously selected antibody pairs with proven specificity. Extensive validation against potential cross-reactivity ensures that even large, complex panels produce accurate, reproducible results. This attention to antibody design allows R&D Systems Luminex multiplex assays to detect analytes at picogram-per-milliliter concentrations— levels that can serve as early warning signs before clinical symptoms emerge.

Generate Reliable, Reproducible Data

With over 50 years of experience, R&D Systems is able to combine validated antibodies, optimized assay design, and stringent quality control processes in every R&D Systems Luminex assay to ensure consistent, high-quality results—even in complex sample matrices such as serum or plasma.

We do this by carefully selecting in-house antibodies to avoid cross-reactivity with substances in the sample and exhaustively testing antibody pairs against related epitopes to ensure analyte specificity. In addition, we have a wide range of diluents that are optimized with blocking reagents to minimize non-specific binding and matrix effects. 

Lastly, all assays are manufactured in an ISO 13485– certified facility and are supported by a robust quality system. 

Reduce Time, and Sample Requirements

By consolidating multiple assays into a single workflow, multiplex immunoassays streamline experimental design—saving time, reducing sample consumption, and accelerating time to results. 

Enabling Translational Success from Discovery to Diagnostics

Successful early cancer detection requires technologies that bridge biomarker discovery and clinical application. The R&D Systems Luminex platform combines high-quality reagents with decades of assay development expertise to support this transition, helping move discoveries toward clinically actionable diagnostics. Case in point is the Oncuria® bladder cancer test from Nonagen Bioscience. Developed using high-quality reagents from R&D Systems, this multiplex immunoassay was shown to have 93% sensitivity and 95% specificity for detecting bladder cancer, with demonstrated consistency across tumor grades and stages. Learn more about Nonagen Bioscience and the development of the Oncuria in the webinar below.

Related Assays

Resources